Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) an...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/4610129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564206406205440 |
|---|---|
| author | Anne-Laurence Best Franck Fajnkuchen Sylvia Nghiem-Buffet Typhaine Grenet Gabriel Quentel Corinne Delahaye-Mazza Salomon Y. Cohen Audrey Giocanti-Aurégan |
| author_facet | Anne-Laurence Best Franck Fajnkuchen Sylvia Nghiem-Buffet Typhaine Grenet Gabriel Quentel Corinne Delahaye-Mazza Salomon Y. Cohen Audrey Giocanti-Aurégan |
| author_sort | Anne-Laurence Best |
| collection | DOAJ |
| description | Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results. Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p<0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p=0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n=55). Discussion/Conclusion. Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. |
| format | Article |
| id | doaj-art-7860637f82de45b9bcb7c9a6c640f008 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-7860637f82de45b9bcb7c9a6c640f0082025-02-03T01:11:32ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/46101294610129Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life SettingAnne-Laurence Best0Franck Fajnkuchen1Sylvia Nghiem-Buffet2Typhaine Grenet3Gabriel Quentel4Corinne Delahaye-Mazza5Salomon Y. Cohen6Audrey Giocanti-Aurégan7Ophthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP, Paris 13 University, Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP, Paris 13 University, Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP, Paris 13 University, Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP, Paris 13 University, Bobigny, FranceCentre d’Imagerie et de Laser, Paris, FranceCentre d’Imagerie et de Laser, Paris, FranceCentre d’Imagerie et de Laser, Paris, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP, Paris 13 University, Bobigny, FrancePurpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results. Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p<0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p=0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n=55). Discussion/Conclusion. Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients.http://dx.doi.org/10.1155/2018/4610129 |
| spellingShingle | Anne-Laurence Best Franck Fajnkuchen Sylvia Nghiem-Buffet Typhaine Grenet Gabriel Quentel Corinne Delahaye-Mazza Salomon Y. Cohen Audrey Giocanti-Aurégan Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting Journal of Ophthalmology |
| title | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
| title_full | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
| title_fullStr | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
| title_full_unstemmed | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
| title_short | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
| title_sort | treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real life setting |
| url | http://dx.doi.org/10.1155/2018/4610129 |
| work_keys_str_mv | AT annelaurencebest treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT franckfajnkuchen treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT sylvianghiembuffet treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT typhainegrenet treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT gabrielquentel treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT corinnedelahayemazza treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT salomonycohen treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT audreygiocantiauregan treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting |